Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Jun 11, 2024 2:47pm
56 Views
Post# 36083246

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Type C Meeting Timings

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Type C Meeting Timingsaccelerated BLA is not accelerated approval...

there are many routes to have a BLA approved in less time than is the normal goal date... Fast Track, Breakthrough designation, Priority Review and Accelerated Approval.

Accelerated Approval is VERY different... approval is granted on a yearly basis, it is conditional, and is determined via a Phase IV trial... Matt has confirmed that Phase III will be traditional kind... so NO AA... why do you continue to mislead.?

words are important. ONCY already has FAST TRACK designation for mBC Phase III, and a SPA in place... and they've been in place for 5 years... 
Just like how ONCY changed it's slide deck to state, registration enabling trials, rather than Phase III..

They are no closer to approval than they were 5 years ago, and Bracelet-1 was a waste of time. They only had to repeat IND-213 - it would have completed by now... but perhaps Matt didn't think believe his own randomised data.... and thouight a Phase III at larger scale would fail... this management is tragic. and the pps says it all.

it's a shame you can't copy and paste some additional brain cells.
<< Previous
Bullboard Posts
Next >>